OBJECTIVES: This report reviews the cost effectiveness of different therapeutic interventions used in the treatment of ankylosing spondylitis (AS). METHODS: We performed a systematic search of the databases MEDLINE via PubMed, EMBASE and the Cochrane Library and used hand-searching to identify articles on cost effectiveness of therapies for adult patients with AS published up to November 2010. RESULTS: Of 135 articles, 13 studies were analysed. Two articles were on physical therapies, one article was on NSAIDs and ten articles were on tumour necrosis factor (TNF) inhibitors (infliximab = 6, etanercept = 2, infliximab and etanercept = 1 and adalimumab = 1). Of the latter, no article directly compared TNF inhibitors. Articles showed substantial heterogeneity in methodological approaches and thus results, which prevented us from any extensive comparison, data pooling or meta-analysis. The incremental cost-effectiveness ratio (ICER) for spa-exercise treatment was &U20AC;7465 (95% CI 3294, 14 686) per QALY. The ICERs for infliximab, etanercept and adalimumab were &U20AC;5307-237 010, &U20AC;29 815-123 761 and &U20AC;7344-33 303 per QALY, respectively. CONCLUSIONS: Modelling treatment strategies in chronic relapsing diseases such as AS presents specific challenges, as reflected in the variation in the cost-effectiveness results reported. Although quite variable, the cost-effectiveness ratios for AS therapies remain within an acceptable range.
OBJECTIVES: This report reviews the cost effectiveness of different therapeutic interventions used in the treatment of ankylosing spondylitis (AS). METHODS: We performed a systematic search of the databases MEDLINE via PubMed, EMBASE and the Cochrane Library and used hand-searching to identify articles on cost effectiveness of therapies for adult patients with AS published up to November 2010. RESULTS: Of 135 articles, 13 studies were analysed. Two articles were on physical therapies, one article was on NSAIDs and ten articles were on tumour necrosis factor (TNF) inhibitors (infliximab = 6, etanercept = 2, infliximab and etanercept = 1 and adalimumab = 1). Of the latter, no article directly compared TNF inhibitors. Articles showed substantial heterogeneity in methodological approaches and thus results, which prevented us from any extensive comparison, data pooling or meta-analysis. The incremental cost-effectiveness ratio (ICER) for spa-exercise treatment was &U20AC;7465 (95% CI 3294, 14 686) per QALY. The ICERs for infliximab, etanercept and adalimumab were &U20AC;5307-237 010, &U20AC;29 815-123 761 and &U20AC;7344-33 303 per QALY, respectively. CONCLUSIONS: Modelling treatment strategies in chronic relapsing diseases such as AS presents specific challenges, as reflected in the variation in the cost-effectiveness results reported. Although quite variable, the cost-effectiveness ratios for AS therapies remain within an acceptable range.
Authors: A Saraux; F Guillemin; P Guggenbuhl; C H Roux; P Fardellone; E Le Bihan; A Cantagrel; I Chary-Valckenaere; L Euller-Ziegler; R-M Flipo; R Juvin; J-M Behier; B Fautrel; C Masson; J Coste Journal: Ann Rheum Dis Date: 2005-04-07 Impact factor: 19.103
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Jeroen P Jansen; Sabine Gaugris; Ernest H Choy; Andrew Ostor; Julian T Nash; Wiro Stam Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: B Fautrel; M Benhamou; M Breban; C Roy; C Lenoir; G Trape; A Baleydier; P Ravaud; M Dougados Journal: Ann Rheum Dis Date: 2009-09-09 Impact factor: 19.103
Authors: John Oldroyd; Lionel Schachna; Rachelle Buchbinder; Margaret Staples; Bridie Murphy; Molly Bond; Andrew Briggs; Marissa Lassere; Lyn March Journal: Int J Rheumatol Date: 2009-08-02
Authors: Maria A T van Wissen; Max M H Teuwen; Cornelia H M van den Ende; Thea P M Vliet Vlieland; Alfons A den Broeder; Wilbert B van den Hout; Wilfred F Peter; Dirkjan van Schaardenburg; Astrid M van Tubergen; Maaike G J Gademan; Salima F E van Weely Journal: Physiother Res Int Date: 2021-11-15